Teleflex Incorporated (TFX)
After hours: 05:38PM EDT
| Previous close | 387.22 |
| Open | 384.48 |
| Bid | 388.52 x 800 |
| Ask | 387.91 x 1000 |
| Day's range | 381.29 - 389.67 |
| 52-week range | 312.33 - 449.38 |
| Volume | 347,348 |
| Avg. volume | 292,969 |
| Market cap | 18.132B |
| Beta (5Y monthly) | 1.19 |
| PE ratio (TTM) | 52.30 |
| EPS (TTM) | 7.41 |
| Earnings date | 27 Oct 2021 - 01 Nov 2021 |
| Forward dividend & yield | 1.36 (0.35%) |
| Ex-dividend date | 13 Aug 2021 |
| 1y target est | 462.55 |
- Simply Wall St.
Could The Market Be Wrong About Teleflex Incorporated (NYSE:TFX) Given Its Attractive Financial Prospects?
Teleflex (NYSE:TFX) has had a rough three months with its share price down 5.2%. However, stock prices are usually...
- GlobeNewswire
Teleflex Announces Large-Scale Analysis of Real-World Healthcare Claims Data for Enlarged Prostate Procedures at the American Urological Association 2021 Annual Meeting
Late-Breaking Data Presentation Reveals How UroLift PUL’s Post-Operative Events Compare With Other Minimally Invasive Procedures and Traditional Surgery for the Treatment of BPHWAYNE, Pa., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) today announced that new real-world healthcare claims data reveal that the risk of return procedures is lowest after treatment with the UroLift® System among the analyzed benign prostatic hyperplasia (BPH) treatment options. The data also show
- Zacks
Teleflex (TFX) Real-World Data Outcome Supports UroLift System
Teleflex's (TFX) new real-world data outcomes together with product launches demonstrate the importance of UroLift System for most BPH patients.
